IJR News - today's news from every side
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
Loading
Genius — OpenServe
News
Home
Popular
Congress
Genius — OpenServe
Trending
FDA panel backs BPC-157 access, Hims shares surge
United States of America
— Jul 23, 2026
An FDA advisory panel recommended adding BPC-157 to the list eligible for pharmacy compounding, a move investors interpreted as a boost to Hims & Hers' telehealth and peptide offerings, with the stock jumping about 10–11% across reports. The company, valued around $8.1 billion, has faced insider selling in the past quarter, and regulators’ signaling comes as it positions itself in a growing peptide therapy market.
+6
0
Share
Study Finds 33-Fold Rise in BPC-157 Use Despite Limited Safety Data
United States Food and Drug Administration
— Sep 15, 2026
BPC-157, an unapproved peptide backed by RFK Jr. and often used with TB-500 as the “Wolverine stack,” is being consumed across a wide range of conditions in the gray market, with new-user numbers rising 33-fold from 2020 to 2026 and regulation still unresolved as the FDA weighs compounding despite safety concerns. Researchers warn that real-world use is hard to track, 1,039 documented patients exist, and there is no solid evidence that the peptide improves healing or pain, underscoring safety risks amid burgeoning popularity.
+2
0
Share
Unapproved Peptides Raise Safety and Purity Concerns
Health
— Oct 13, 2026
Health experts and patients warn that unapproved peptides such as BPC-157, promoted online for weight loss, injury recovery and other benefits, have not been adequately tested and may cause serious harm. Reports of adverse effects and growing use have renewed concern about widening access to these compounds, while physicians distinguish them from FDA-approved peptide medicines.
+16
0
Share
FDA Panel Recommends Loosening Peptide Compounding Rules
Health
— Jul 20, 2026
The FDA Pharmacy Compounding Advisory Committee is set to review seven peptide compounds, including BPC-157 and TB-500, to decide whether licensed pharmacies can make them, amid rising social-media-driven interest and largely unclear evidence of safety and effectiveness. Regulators caution the evidence base is limited as demand grows, with endorsements from public figures fueling interest and some users reporting benefits.
+75
0
Share
IJR
US Forces Shoot Down Iranian Attack Drones Targeting Middle Eastern Country
Jillian Butler · 2 min · 3h
